omeprazole has been researched along with Pyrosis in 132 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Excerpt | Relevance | Reference |
---|---|---|
"Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions." | 9.69 | Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023) |
"Endoscopy-negative patients with heartburn who failed once daily PPIs were randomly allocated to receive 6 weeks treatment of fluoxetine, omeprazole, or placebo." | 9.19 | Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. ( Barzin, G; Emami, H; Farrokhi-Khajeh-Pasha, Y; Fotouhi, A; Hajifathalian, K; Mirbagheri, SA; Mirbagheri, SS; Ostovaneh, MR; Saeidi, B, 2014) |
"To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux." | 9.11 | Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005) |
"To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease." | 9.11 | Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
"To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)." | 9.10 | Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002) |
" Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | 9.10 | Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
"Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease." | 9.10 | A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002) |
"The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease." | 9.09 | Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000) |
"05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 9.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
"214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half the days over the past 6 months and during the 7- to 10-day pre-treatment period) were randomized to either lansoprazole 15 mg or lansoprazole 30 mg, or placebo o." | 9.09 | Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. ( Fisher, R; Greski-Rose, PA; Huang section sign, B; Kovacs, TO; Richter, JE, 1999) |
"In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0." | 9.09 | Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999) |
"Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom." | 9.09 | Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A; Wiklund, I, 1999) |
"This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis." | 9.09 | Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001) |
"Previous studies have demonstrated greater efficacy for omeprazole compared with cimetidine in patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (GERD) patients with reflux symptoms but without endoscopic abnormality." | 9.08 | Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. ( Axon, AT; Bate, CM; Emmas, CE; Green, JR; Murray, FE; Taylor, MD; Tildesley, G, 1997) |
"Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study." | 9.08 | Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997) |
" This study assessed 20 mg omeprazole daily (OM20), 10 mg omeprazole daily (OM10), and 150 mg ranitidine (RAN) twice daily for symptom relief in gastro-oesophageal reflux disease (GORD)." | 9.08 | Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. ( Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL; Wilcock, C, 1997) |
"Patients with heartburn, without endoscopic signs of oesophagitis, were randomized to double-blind treatment with omeprazole, 20 or 10 mg once daily, or placebo, for 4 weeks (n = 509)." | 9.08 | Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A, 1997) |
"To examine dyspepsia symptom relief over 16 weeks and compare an omeprazole clinical management strategy with a commonly used combination of antacid-alginate followed by H2-antagonist." | 9.08 | The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. ( Evans, WM; Mason, I; Millar, LJ; Sheikh, RR; Taylor, MD; Todd, PL; Turbitt, ML, 1998) |
" is more effective than cimetidine 800 mg nocte in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis." | 9.08 | Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. ( Axon, AT; Bate, CM; Emmas, C; Green, JR; Murrays, FE; Owen, SM; Taylor, MD; Tildesley, G, 1998) |
"To define the optimum doses of omeprazole appropriate for acute and long-term therapy of patients with gastro-oesophageal reflux disease, 24-h oesophageal pH was measured in 12 patients with symptomatic reflux and an abnormal 24-h oesophageal acid exposure time (greater than 6%) in a randomized, double-blind, four-way crossover study comparing the effects of omeprazole 10, 20, or 40 mg/day and placebo." | 9.07 | Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. ( Allen, ML; Bradstreet, TE; Cagliola, AJ; Humphries, TJ; Maton, PN; McIntosh, D; Robinson, M, 1991) |
"To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 8.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
"To report a case of chronic, persistent cough induced by omeprazole therapy." | 7.72 | Omeprazole-induced intractable cough. ( Delafosse, C; Howaizi, M, 2003) |
"Heartburn was controlled on lansoprazole 30 mg/per day in 76." | 7.72 | Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003) |
"A 3-month observational study was conducted in an OTC setting to determine whether consumers could (1) correctly self-select to use omeprazole for frequent heartburn, (2) comply with a product label that calls for 14 consecutive days of once-daily dosing, and (3) use more than 14 doses of medication only under the advice of a physician." | 7.72 | Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. ( Allgood, G; Allgood, L; Fendrick, AM; Grender, J; Peura, D; Schachtel, B; Shaw, M, 2004) |
"To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease." | 7.71 | Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002) |
"Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis." | 7.69 | Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. ( Delgaudio, JM; Grist, WJ; Gussack, G; Waring, JP; Wo, JM, 1997) |
" These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms." | 6.71 | Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003) |
"In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0." | 6.71 | Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004) |
"Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions." | 5.69 | Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023) |
"Patients who were referred to Veterans Affairs (VA) gastroenterology clinics for PPI-refractory heartburn received 20 mg of omeprazole twice daily for 2 weeks, and those with persistent heartburn underwent endoscopy, esophageal biopsy, esophageal manometry, and multichannel intraluminal impedance-pH monitoring." | 5.30 | Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. ( Biswas, K; Castell, DO; Chan, BS; Chey, WD; Davis-Karim, A; Dunbar, KB; Fernando, RS; Gellad, ZF; Genta, RM; Ghaferi, AA; Huang, GD; Hunter, JG; Jackson, CS; Jones, KM; Kaz, AM; Kim, AW; Kim, T; Lagoo-Deenadayalan, S; Laine, L; Lee, R; Lieberman, D; Lo, WK; Mashimo, H; Melton, SD; Murthy, UK; Paski, SC; Pearl, JP; Pham, TH; Provenzale, D; Rubenstein, JH; Sanchez, VM; Serpi, T; Smith, BR; Souza, RF; Spechler, SJ; Tatum, RP; von Rosenvinge, EC; Wallen, JM; Warren, SR, 2019) |
"Patients with persistent heartburn symptoms ≥ 3 times per week treated with omeprazole 20 mg daily were enrolled and randomized to commonly recommended dosing or continued suboptimal dosing of omeprazole." | 5.30 | Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial). ( Perzynski, AT; Votruba, M; Waghray, A; Waghray, N; Wolfe, MM, 2019) |
"Zegerid (on demand immediate-release omeprazole and sodium bicarbonate combination therapy) has demonstrated earlier absorption and more rapid pH change compared with Losec (standard enteric coated omeprazole), suggesting more rapid clinical relief of heartburn." | 5.20 | Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec. ( Gruss, HJ; Jones, D; Ng Kwet Shing, R; Reguła, J; Walker, D, 2015) |
"Endoscopy-negative patients with heartburn who failed once daily PPIs were randomly allocated to receive 6 weeks treatment of fluoxetine, omeprazole, or placebo." | 5.19 | Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. ( Barzin, G; Emami, H; Farrokhi-Khajeh-Pasha, Y; Fotouhi, A; Hajifathalian, K; Mirbagheri, SA; Mirbagheri, SS; Ostovaneh, MR; Saeidi, B, 2014) |
"Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis." | 5.14 | Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. ( Zheng, RN, 2009) |
"Patients with heartburn for at least 2 days a week during the month before entry into the study and no endoscopic signs of a mucosal break (grade M or N according to Hoshihara's modification of the Los Angeles classification) were randomly assigned to one of three groups (omeprazole 10 mg or 20 mg, or placebo) once daily for 4 weeks." | 5.13 | Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. ( Chiba, T; Chikama, T; Inokuchi, H; Kawamura, S; Murakami, A; Serizawa, H; Tanabe, S; Tsuru, T; Uemura, N; Umezu, T; Urata, T; Yamamoto, M; Yamauchi, M; Yoshida, T; Yurino, N, 2008) |
"Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
"Heartburn-dominant uninvestigated dyspepsia patients from 46 primary care centres were randomized to one of two active treatment strategies: omeprazole 20 mg daily (proton pump inhibitor-start) or ranitidine 150 mg bid (H2-receptor antagonist-start) for the first 4-8 weeks, stepping up to omeprazole 40 or 20 mg daily, respectively, for 4-8 weeks for persistent symptoms." | 5.11 | Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Sinclair, P; Smyth, S; Thomson, AB; Veldhuyzen van Zanten, SJ; White, RJ, 2005) |
"To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux." | 5.11 | Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005) |
"To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease." | 5.11 | Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
" Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | 5.10 | Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
"Data were pooled on patients (n = 826) with a diagnosis of functional dyspepsia from two placebo-controlled trials who were treated with omeprazole, 10 or 20 mg once daily, for 4 weeks." | 5.10 | Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? ( Bolling-Sternevald, E; Glise, H; Junghard, O; Lauritsen, K; Talley, NJ, 2003) |
"Rabeprazole may be more effective than omeprazole and lansoprazole for the rapid relief of heartburn symptoms in patients with reflux esophagitis." | 5.10 | Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. ( Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003) |
" In 16 subjects with chronic heartburn, 24-hr gastric and esophageal pH were measured at baseline and again after six days of 20 mg omeprazole alone at 08:00 hr followed by placebo, 75 mg ranitidine, or 20 mg omeprazole at 22:00 hr." | 5.10 | Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. ( Ciociola, AA; Filinto, J; Gardner, JD; Miner, PB; Robinson, M; Rodriguez-Stanley, S; Zubaidi, S, 2002) |
"The 'Future of Acid Suppression Therapy' (FAST) trial evaluated, in actual clinical practice, the timing of symptom relief, changes in symptom severity, health-related quality of life and safety in endoscopically confirmed erosive gastro-oesophageal reflux disease treated with rabeprazole." | 5.10 | Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. ( Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M, 2002) |
"To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)." | 5.10 | Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002) |
"Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease." | 5.10 | A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002) |
"Oesophageal pH and heartburn severity were determined in 27 GERD subjects at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way crossover fashion." | 5.10 | Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
"05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 5.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
"The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease." | 5.09 | Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000) |
"This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis." | 5.09 | Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001) |
"Our objective was to compare four management strategies for heartburn: therapy with an H2-receptor antagonist (ranitidine), therapy with a proton pump inhibitor (lansoprazole), crossover from ranitidine to lansoprazole ("step-up" therapy), and crossover from lansoprazole to ranitidine ("step-down" therapy)." | 5.09 | Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. ( Freston, JW; Henning, JM; Howden, CW; Huang, B; Lukasik, N, 2001) |
"In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0." | 5.09 | Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999) |
"214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half the days over the past 6 months and during the 7- to 10-day pre-treatment period) were randomized to either lansoprazole 15 mg or lansoprazole 30 mg, or placebo o." | 5.09 | Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. ( Fisher, R; Greski-Rose, PA; Huang section sign, B; Kovacs, TO; Richter, JE, 1999) |
"Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom." | 5.09 | Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A; Wiklund, I, 1999) |
"To compare the effects and tolerability of omeprazole and cisapride with that of placebo for control of heartburn in primary care patients." | 5.09 | Heartburn treatment in primary care: randomised, double blind study for 8 weeks. ( Bernklev, T; Berstad, A; Hatlebakk, JG; Hyggen, A; Madsen, PH; Mowinckel, P; Schulz, T; Walle, PO, 1999) |
"Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study." | 5.08 | Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997) |
" This study assessed 20 mg omeprazole daily (OM20), 10 mg omeprazole daily (OM10), and 150 mg ranitidine (RAN) twice daily for symptom relief in gastro-oesophageal reflux disease (GORD)." | 5.08 | Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. ( Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL; Wilcock, C, 1997) |
"Patients with heartburn, without endoscopic signs of oesophagitis, were randomized to double-blind treatment with omeprazole, 20 or 10 mg once daily, or placebo, for 4 weeks (n = 509)." | 5.08 | Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A, 1997) |
"To examine dyspepsia symptom relief over 16 weeks and compare an omeprazole clinical management strategy with a commonly used combination of antacid-alginate followed by H2-antagonist." | 5.08 | The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. ( Evans, WM; Mason, I; Millar, LJ; Sheikh, RR; Taylor, MD; Todd, PL; Turbitt, ML, 1998) |
"Previous studies have demonstrated greater efficacy for omeprazole compared with cimetidine in patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (GERD) patients with reflux symptoms but without endoscopic abnormality." | 5.08 | Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. ( Axon, AT; Bate, CM; Emmas, CE; Green, JR; Murray, FE; Taylor, MD; Tildesley, G, 1997) |
" is more effective than cimetidine 800 mg nocte in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis." | 5.08 | Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. ( Axon, AT; Bate, CM; Emmas, C; Green, JR; Murrays, FE; Owen, SM; Taylor, MD; Tildesley, G, 1998) |
"In our study omeprazole was superior to either lansoprazole or pantoprazole in the maintenance treatment of complicated gastro-oesophageal reflux disease." | 5.08 | A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. ( Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H, 1998) |
" Eighty-eight patients with healed erosive/ulcerative oesophagitis and relief of heartburn after pre-treatment with omeprazole received maintenance treatment." | 5.08 | Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease. ( Aalykke, C; Havelund, T; Rasmussen, L, 1997) |
"To define the optimum doses of omeprazole appropriate for acute and long-term therapy of patients with gastro-oesophageal reflux disease, 24-h oesophageal pH was measured in 12 patients with symptomatic reflux and an abnormal 24-h oesophageal acid exposure time (greater than 6%) in a randomized, double-blind, four-way crossover study comparing the effects of omeprazole 10, 20, or 40 mg/day and placebo." | 5.07 | Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. ( Allen, ML; Bradstreet, TE; Cagliola, AJ; Humphries, TJ; Maton, PN; McIntosh, D; Robinson, M, 1991) |
"The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief." | 4.95 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017) |
"To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 4.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
"Patients who had heartburn twice a week or more were treated with 20 mg omeprazole (OPZ) once daily for 8 wk as an initial therapy (study 1)." | 3.77 | Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. ( Fujiwara, A; Ishioka, H; Kawahara, Y; Nasu, J; Okada, H; Takenaka, R; Tsuzuki, T; Yamamoto, K; Yoshinaga, F, 2011) |
" Patients were assessed for complete relief of heartburn (absence of symptoms in the preceding 7 days) after 4 weeks' treatment (omeprazole 10 or 20 mg once daily; ranitidine 150 mg twice daily)." | 3.73 | Psychological factors as a predictor of treatment response in patients with heartburn: a pooled analysis of clinical trials. ( Carlsson, J; Carlsson, R; Glise, H; Wiklund, I, 2006) |
"To report a case of chronic, persistent cough induced by omeprazole therapy." | 3.72 | Omeprazole-induced intractable cough. ( Delafosse, C; Howaizi, M, 2003) |
"A 3-month observational study was conducted in an OTC setting to determine whether consumers could (1) correctly self-select to use omeprazole for frequent heartburn, (2) comply with a product label that calls for 14 consecutive days of once-daily dosing, and (3) use more than 14 doses of medication only under the advice of a physician." | 3.72 | Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. ( Allgood, G; Allgood, L; Fendrick, AM; Grender, J; Peura, D; Schachtel, B; Shaw, M, 2004) |
"Heartburn was controlled on lansoprazole 30 mg/per day in 76." | 3.72 | Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003) |
"To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease." | 3.71 | Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002) |
"We analysed baseline and follow-up assessments of heartburn symptoms and HRQL scores from three clinical trials (total n=1351) comparing omeprazole and ranitidine for acute symptomatic treatment of GERD." | 3.70 | Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. ( Crawley, JA; Joelsson, BO; Levine, DS; Revicki, DA; Zodet, MW, 1999) |
" A further evaluation was undertaken in patients with symptoms suggestive of GERD and in patients with non-ulcer dyspepsia, to identify factors that might predict symptom relief during treatment with omeprazole." | 3.70 | The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. ( Bolling-Sternevald, E; Carlsson, R; Dent, J; Johnsson, F; Junghard, O; Lauritsen, K; Lundell, L; Riley, S, 1998) |
"Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis." | 3.69 | Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. ( Delgaudio, JM; Grist, WJ; Gussack, G; Waring, JP; Wo, JM, 1997) |
"The burden of gastroesophageal reflux disease (GERD) is increasing in the Asia area and the majority of GERD patients have non-erosive reflux disease (NERD)." | 2.78 | Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. ( Chang, JJ; Chen, LW; Chen, TH; Chiu, CT; Hsu, CM; Lin, CJ; Su, MY; Sung, CM; Wang, CC, 2013) |
"pylori) eradication on gastroesophageal reflux disease is controversial." | 2.71 | The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. ( Güliter, S; Kandilci, U, 2004) |
"In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0." | 2.71 | Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004) |
" These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms." | 2.71 | Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003) |
"Esomeprazole 40 mg is an effective and safe drug at least comparable to omeprazole in treating Chinese EE patients." | 2.71 | Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. ( Chang, FY; Chen, CY; Lai, YL; Lee, SD; Lu, CL; Luo, JC, 2005) |
"Management costs for gastroesophageal reflux disease are high because of the expensive medications used for maintenance therapy." | 2.71 | Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. ( Bernard, L; Fendrick, AM; Inadomi, JM; McIntyre, L, 2003) |
"Esomeprazole 40 mg was also significantly more effective than omeprazole for healing at week 4 and for all secondary variables evaluating heartburn resolution." | 2.69 | Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. ( Collins, DW; D'Amico, D; Falk, GW; Hamelin, B; Joelsson, B; Johnson, DA; Kahrilas, PJ; Schmitt, C; Whipple, J, 2000) |
"Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0." | 2.68 | Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. ( Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ, 1997) |
"Omeprazole is a highly effective treatment for peptic esophagitis." | 2.66 | Healing and relapse of severe peptic esophagitis after treatment with omeprazole. ( Beveridge, BR; Dent, J; Gibson, GG; Hetzel, DJ; Laurence, BH; Mackinnon, M; McCarthy, JH; Mitchell, B; Narielvala, FM; Reed, WD, 1988) |
"Unexplained chest pain is potentially attributable to gastro-oesophageal reflux disease (GORD) or oesophageal motility disorders." | 2.47 | Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011) |
"The consequences of nocturnal gastroesophageal reflux disease (GERD) may be greater than daytime GERD in terms of clinical complications such as increased risk of esophageal lesions and respiratory conditions, as well as issues of health-related quality of life, sleep, work productivity, and economics." | 2.44 | Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. ( Johnson, DA; Katz, PO, 2008) |
"Whether these patients are part of the GERD spectrum or have another diagnosis is not clear." | 2.43 | Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. ( DeVault, KR, 2006) |
"Gastroesophageal reflux disease (GERD) is defined as 'Chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus'." | 2.42 | [Significance of PPI-test in the diagnosis of GERD]. ( Ichimura, H; Kuwayama, H; Nishiki, R; Takada, H; Takahashi, M, 2004) |
"Heartburn and other symptoms of gastroesophageal reflux disease can be a lifelong problem, affecting millions of Americans each year." | 2.40 | A practical approach to heartburn. ( Castell, DO, 1999) |
"Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60." | 1.72 | Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022) |
"Eight patients (17%) with relapse of dysphagia were referred to laparoscopic Heller myotomy with no surgical complication." | 1.36 | Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results. ( Dolina, J; Hep, A; Kroupa, R; Matyasova, Z; Mrazova, J; Novotny, I; Prokesova, J; Sedmik, J; Valek, V, 2010) |
"Duodenal ulcer (DU) and gastroesophageal reflux disease (GERD) are often combined." | 1.34 | [Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease]. ( Tsimmerman, IaS; Vologzhanina, LG, 2007) |
"Gastro-oesophageal reflux disease is one of the most common diseases in primary care and has a significant negative impact on patients' quality of life." | 1.33 | Validation of the Reflux Disease Questionnaire for a German population. ( Kulig, M; Leodolter, A; Malfertheiner, P; Nocon, M; Willich, SN, 2005) |
"Severity and frequency of gastroesophageal reflux disease (GERD) related symptoms are associated with impaired health-related quality of life (HRQL)." | 1.32 | Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. ( Crawley, JA; Joshua-Gotlib, S; Levine, D; Revicki, DA; Zodet, MW, 2003) |
"Patients with gastro-oesophageal reflux disease (GORD) frequently report that meals high in fat worsen heartburn." | 1.31 | Duodenal fat intensifies the perception of heartburn. ( Elashoff, JD; Fass, R; Lembo, A; Mayer, EA; Meyer, JH, 2001) |
"Strategies to prevent Barrett's-related esophageal cancer have focused on reversal of Barrett's using pharmacological or surgical antireflux therapies and endoscopically-induced injury." | 1.31 | Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression? ( Fennerty, MB, 2002) |
"Idiopathic hoarseness as a single symptom increases the odds ratio for laryngopharyngeal reflux disease 85 times." | 1.31 | [Typical and atypical symptoms of laryngopharyngeal reflux disease]. ( Jonaitis, L; Pribuisiene, R; Uloza, V, 2002) |
"Only surgery improved regurgitation." | 1.30 | The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. ( Gadenstaetter, M; Glaser, K; Hinder, RA; Profanter, C; Wetscher, GJ, 1999) |
"Gastroesophageal reflux may be responsible for atypical symptoms such as chronic cough and hoarseness." | 1.29 | Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy. ( Hunter, J; Katz, E; Lacayo, L; Suwak, B; Waring, JP, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (0.76) | 18.7374 |
1990's | 30 (22.73) | 18.2507 |
2000's | 78 (59.09) | 29.6817 |
2010's | 19 (14.39) | 24.3611 |
2020's | 4 (3.03) | 2.80 |
Authors | Studies |
---|---|
Vaezi, MF | 1 |
Brunton, S | 1 |
Mark Fendrick, A | 1 |
Howden, CW | 3 |
Atkinson, C | 1 |
Pelletier, C | 1 |
Jacob, R | 1 |
Spechler, SJ | 2 |
Barberio, B | 1 |
Visaggi, P | 1 |
Savarino, E | 2 |
de Bortoli, N | 1 |
Black, CJ | 1 |
Ford, AC | 1 |
Corazziari, ES | 1 |
Gasbarrini, A | 1 |
D'Alba, L | 1 |
D'Ovidio, V | 1 |
Riggio, O | 1 |
Passaretti, S | 1 |
Annibale, B | 1 |
Cicala, M | 1 |
Repici, A | 1 |
Bassotti, G | 1 |
Ciacci, C | 1 |
Di Sabatino, A | 1 |
Neri, M | 1 |
Bragazzi, MC | 1 |
Ribichini, E | 1 |
Radocchia, G | 1 |
Iovino, P | 1 |
Marazzato, M | 1 |
Schippa, S | 1 |
Badiali, D | 1 |
Hunter, JG | 1 |
Jones, KM | 1 |
Lee, R | 1 |
Smith, BR | 1 |
Mashimo, H | 1 |
Sanchez, VM | 1 |
Dunbar, KB | 1 |
Pham, TH | 1 |
Murthy, UK | 1 |
Kim, T | 1 |
Jackson, CS | 1 |
Wallen, JM | 1 |
von Rosenvinge, EC | 1 |
Pearl, JP | 1 |
Laine, L | 1 |
Kim, AW | 1 |
Kaz, AM | 1 |
Tatum, RP | 1 |
Gellad, ZF | 1 |
Lagoo-Deenadayalan, S | 1 |
Rubenstein, JH | 1 |
Ghaferi, AA | 1 |
Lo, WK | 1 |
Fernando, RS | 1 |
Chan, BS | 1 |
Paski, SC | 1 |
Provenzale, D | 1 |
Castell, DO | 2 |
Lieberman, D | 1 |
Souza, RF | 1 |
Chey, WD | 1 |
Warren, SR | 1 |
Davis-Karim, A | 1 |
Melton, SD | 1 |
Genta, RM | 1 |
Serpi, T | 1 |
Biswas, K | 1 |
Huang, GD | 1 |
Thélin, CS | 1 |
Richter, JE | 4 |
Li, MJ | 1 |
Li, Q | 1 |
Sun, M | 1 |
Liu, LQ | 1 |
Waghray, A | 1 |
Waghray, N | 1 |
Perzynski, AT | 1 |
Votruba, M | 1 |
Wolfe, MM | 1 |
Kim, JH | 1 |
Lee, YC | 1 |
Kim, EH | 1 |
Park, JC | 1 |
Shin, SK | 1 |
Lee, SK | 1 |
Jung, DH | 1 |
Park, JJ | 1 |
Youn, YH | 1 |
Park, H | 1 |
Beales, ILP | 1 |
Chiu, CT | 1 |
Hsu, CM | 1 |
Wang, CC | 1 |
Chang, JJ | 1 |
Sung, CM | 1 |
Lin, CJ | 1 |
Chen, LW | 1 |
Su, MY | 1 |
Chen, TH | 1 |
Ostovaneh, MR | 1 |
Saeidi, B | 1 |
Hajifathalian, K | 1 |
Farrokhi-Khajeh-Pasha, Y | 1 |
Fotouhi, A | 1 |
Mirbagheri, SS | 1 |
Emami, H | 1 |
Barzin, G | 1 |
Mirbagheri, SA | 1 |
Walker, D | 1 |
Ng Kwet Shing, R | 1 |
Jones, D | 1 |
Gruss, HJ | 1 |
Reguła, J | 1 |
Toseef, MU | 1 |
Saeed, A | 1 |
Mohi-Ud-Din, E | 1 |
Usmanghani, K | 1 |
Nazar, H | 1 |
Nawaz, A | 1 |
Ahmad, I | 1 |
Siddiqui, FA | 1 |
Johnson, DA | 2 |
Katz, PO | 1 |
Uemura, N | 1 |
Inokuchi, H | 1 |
Serizawa, H | 1 |
Chikama, T | 1 |
Yamauchi, M | 1 |
Tsuru, T | 1 |
Umezu, T | 1 |
Urata, T | 1 |
Yurino, N | 1 |
Tanabe, S | 1 |
Yoshida, T | 1 |
Kawamura, S | 1 |
Murakami, A | 1 |
Yamamoto, M | 1 |
Chiba, T | 1 |
Zheng, RN | 1 |
McColl, KE | 1 |
Gillen, D | 1 |
Kroupa, R | 1 |
Hep, A | 1 |
Dolina, J | 1 |
Valek, V | 1 |
Matyasova, Z | 1 |
Prokesova, J | 1 |
Mrazova, J | 1 |
Sedmik, J | 1 |
Novotny, I | 1 |
de Leone, A | 2 |
Tonini, M | 1 |
Dominici, P | 2 |
Grossi, E | 2 |
Pace, F | 3 |
Riegler, G | 1 |
Tsuzuki, T | 1 |
Okada, H | 1 |
Kawahara, Y | 1 |
Takenaka, R | 1 |
Nasu, J | 1 |
Ishioka, H | 1 |
Fujiwara, A | 1 |
Yoshinaga, F | 1 |
Yamamoto, K | 1 |
Kahrilas, PJ | 4 |
Hughes, N | 1 |
Manabe, N | 1 |
Haruma, K | 1 |
Ito, M | 1 |
Takahashi, N | 1 |
Takasugi, H | 1 |
Wada, Y | 1 |
Nakata, H | 1 |
Katoh, T | 1 |
Miyamoto, M | 1 |
Tanaka, S | 1 |
Ndraha, S | 1 |
Robb-Nicholson, C | 2 |
Reimer, C | 1 |
Bytzer, P | 3 |
Talley, NJ | 3 |
Moore, MG | 1 |
Sprogis, A | 1 |
Katelaris, P | 1 |
Pribuisiene, R | 1 |
Uloza, V | 1 |
Jonaitis, L | 1 |
Fennerty, MB | 1 |
Bolling-Sternevald, E | 2 |
Lauritsen, K | 4 |
Junghard, O | 6 |
Glise, H | 4 |
Laheij, RJ | 1 |
Van Rossum, LG | 1 |
Jansen, JB | 1 |
Verheugt, FW | 1 |
Gardner, JD | 2 |
Sloan, S | 1 |
Robinson, M | 6 |
Miner, PB | 2 |
Paré, P | 1 |
Armstrong, D | 2 |
Pericak, D | 1 |
Pyzyk, M | 1 |
Inadomi, JM | 1 |
McIntyre, L | 1 |
Bernard, L | 1 |
Fendrick, AM | 2 |
Howaizi, M | 1 |
Delafosse, C | 1 |
Pehlivanov, ND | 1 |
Olyaee, M | 1 |
Sarosiek, I | 1 |
McCallum, RW | 1 |
Revicki, DA | 2 |
Zodet, MW | 2 |
Joshua-Gotlib, S | 1 |
Levine, D | 1 |
Crawley, JA | 2 |
Füessl, HS | 1 |
Vakil, N | 1 |
Orr, WC | 1 |
Abu Farsakh, N | 1 |
Adachi, K | 1 |
Hashimoto, T | 1 |
Hamamoto, N | 1 |
Hirakawa, K | 1 |
Niigaki, M | 1 |
Miyake, T | 1 |
Taniura, H | 1 |
Ono, M | 1 |
Kaji, T | 1 |
Suetsugu, H | 1 |
Yagi, J | 1 |
Komazawa, Y | 1 |
Mihara, T | 1 |
Katsube, T | 1 |
Fujishiro, H | 1 |
Shizuku, T | 1 |
Hattori, S | 1 |
Yamamoto, S | 1 |
Kinoshita, Y | 1 |
Carlsson, R | 5 |
Lind, T | 3 |
Shaw, M | 1 |
Schachtel, B | 1 |
Allgood, L | 1 |
Allgood, G | 1 |
Grender, J | 1 |
Peura, D | 1 |
Blum, A | 1 |
De Herdt, D | 1 |
Dubois, D | 1 |
Takahashi, M | 1 |
Nishiki, R | 1 |
Ichimura, H | 1 |
Takada, H | 1 |
Kuwayama, H | 1 |
Juul-Hansen, P | 1 |
Rydning, A | 2 |
Güliter, S | 1 |
Kandilci, U | 1 |
Dent, J | 3 |
Rajabally, YA | 1 |
Jacob, S | 1 |
Bochenek, WJ | 1 |
Mack, ME | 1 |
Fraga, PD | 1 |
Metz, DC | 1 |
Madan, K | 1 |
Ahuja, V | 1 |
Kashyap, PC | 1 |
Sharma, MP | 1 |
Nocon, M | 1 |
Kulig, M | 1 |
Leodolter, A | 1 |
Malfertheiner, P | 1 |
Willich, SN | 1 |
Calabrese, C | 1 |
Bortolotti, M | 1 |
Fabbri, A | 1 |
Areni, A | 1 |
Cenacchi, G | 1 |
Scialpi, C | 1 |
Miglioli, M | 1 |
Di Febo, G | 1 |
Calleja, JL | 1 |
Suarez, M | 1 |
De Tejada, AH | 1 |
Navarro, A | 1 |
Allgood, LD | 1 |
Grender, JM | 1 |
Shaw, MJ | 1 |
Peura, DA | 1 |
Taghavi, SA | 1 |
Ghasedi, M | 1 |
Saberi-Firoozi, M | 1 |
Alizadeh-Naeeni, M | 1 |
Bagheri-Lankarani, K | 1 |
Kaviani, MJ | 1 |
Hamidpour, L | 1 |
Veldhuyzen van Zanten, SJ | 1 |
Barkun, AN | 1 |
Chiba, N | 1 |
Thomson, AB | 1 |
Smyth, S | 1 |
Sinclair, P | 1 |
Chakraborty, B | 1 |
White, RJ | 1 |
Ott, EA | 1 |
Mazzoleni, LE | 1 |
Edelweiss, MI | 1 |
Sander, GB | 1 |
Wortmann, AC | 1 |
Theil, AL | 1 |
Somm, G | 1 |
Cartell, A | 1 |
Rivero, LF | 1 |
Uchôa, DM | 1 |
Francesconi, CF | 1 |
Prolla, JC | 1 |
Zentilin, P | 1 |
Accornero, L | 1 |
Dulbecco, P | 1 |
Savarino, V | 1 |
Chen, CY | 1 |
Lu, CL | 1 |
Luo, JC | 1 |
Chang, FY | 1 |
Lee, SD | 1 |
Lai, YL | 1 |
Inamori, M | 1 |
Togawa, J | 1 |
Iwasaki, T | 1 |
Ozawa, Y | 1 |
Kikuchi, T | 1 |
Muramatsu, K | 1 |
Chiguchi, G | 1 |
Matsumoto, S | 1 |
Kawamura, H | 1 |
Abe, Y | 1 |
Kirikoshi, H | 1 |
Kobayashi, N | 1 |
Shimamura, T | 1 |
Kubota, K | 1 |
Sakaguchi, T | 1 |
Saito, S | 1 |
Ueno, N | 1 |
Nakajima, A | 1 |
Tsuji, S | 1 |
Kawano, S | 1 |
Wada, T | 1 |
Sasaki, M | 1 |
Kataoka, H | 1 |
Tanida, S | 1 |
Itoh, K | 1 |
Ogasawara, N | 1 |
Oshima, T | 1 |
Togawa, S | 1 |
Kubota, E | 1 |
Yamada, T | 1 |
Mori, Y | 1 |
Fujita, F | 1 |
Ohara, H | 1 |
Nakao, H | 1 |
Sobue, S | 1 |
Joh, T | 1 |
Itoh, M | 1 |
Annese, V | 1 |
Prada, A | 1 |
Zambelli, A | 1 |
Casalini, S | 1 |
Nardini, P | 1 |
Bianchi Porro, G | 1 |
Mine, S | 1 |
Iida, T | 1 |
Tabata, T | 1 |
Kishikawa, H | 1 |
Tanaka, Y | 1 |
Bigard, MA | 1 |
Genestin, E | 1 |
DeVault, KR | 1 |
Wiklund, I | 2 |
Carlsson, J | 1 |
Dohmen, W | 1 |
Fuchs, W | 1 |
Anandasabapathy, S | 1 |
Jaffin, BW | 1 |
Tsimmerman, IaS | 1 |
Vologzhanina, LG | 1 |
Halling, K | 1 |
Umeda, N | 1 |
Miki, K | 1 |
Hoshino, E | 1 |
Collen, MJ | 1 |
Strong, RM | 1 |
Waring, JP | 2 |
Lacayo, L | 1 |
Hunter, J | 1 |
Katz, E | 1 |
Suwak, B | 1 |
Shoenut, JP | 1 |
Wieler, JA | 1 |
Micflikier, AB | 1 |
Loizeau, E | 1 |
Decktor, DL | 1 |
Maton, PN | 2 |
Sabesin, S | 2 |
Roufail, W | 1 |
Kogut, D | 1 |
Roberts, W | 1 |
McCullough, A | 1 |
Pardoll, P | 1 |
Saco, L | 1 |
Sontag, SJ | 2 |
Kogut, DG | 1 |
Fleischmann, R | 1 |
Campbell, DR | 2 |
Richter, J | 1 |
McFarland, M | 1 |
Lehman, GA | 1 |
Castell, D | 1 |
Havelund, T | 3 |
Aalykke, C | 1 |
Rasmussen, L | 1 |
Bate, CM | 2 |
Green, JR | 2 |
Axon, AT | 2 |
Murray, FE | 1 |
Tildesley, G | 2 |
Emmas, CE | 1 |
Taylor, MD | 3 |
Galmiche, JP | 1 |
Barthelemy, P | 1 |
Hamelin, B | 2 |
Venables, TL | 1 |
Newland, RD | 1 |
Patel, AC | 1 |
Hole, J | 1 |
Wilcock, C | 1 |
Turbitt, ML | 2 |
Anker-Hansen, O | 2 |
Hernqvist, H | 2 |
Lundell, L | 3 |
Pedersen, SA | 2 |
Stubberöd, A | 2 |
Parks, SM | 1 |
Wo, JM | 1 |
Grist, WJ | 1 |
Gussack, G | 1 |
Delgaudio, JM | 1 |
Katz, P | 1 |
Mason, I | 1 |
Millar, LJ | 1 |
Sheikh, RR | 1 |
Evans, WM | 1 |
Todd, PL | 1 |
Murrays, FE | 1 |
Owen, SM | 1 |
Emmas, C | 1 |
Jaspersen, D | 1 |
Diehl, KL | 1 |
Schoeppner, H | 1 |
Geyer, P | 1 |
Martens, E | 1 |
Johnsson, F | 1 |
Riley, S | 1 |
Jones, R | 1 |
Crouch, SL | 1 |
Wetscher, GJ | 1 |
Glaser, K | 1 |
Gadenstaetter, M | 1 |
Profanter, C | 1 |
Hinder, RA | 2 |
Kovacs, TO | 2 |
Greski-Rose, PA | 1 |
Huang section sign, B | 1 |
Fisher, R | 1 |
Johnston, BT | 1 |
Hatlebakk, JG | 2 |
Hyggen, A | 1 |
Madsen, PH | 1 |
Walle, PO | 1 |
Schulz, T | 1 |
Mowinckel, P | 1 |
Bernklev, T | 1 |
Berstad, A | 2 |
Wilhelmsen, I | 1 |
Olafsson, S | 1 |
Levine, DS | 1 |
Joelsson, BO | 1 |
Vernet Vernet, M | 1 |
Roca Figueras, G | 1 |
Jovell Fernández, E | 1 |
Iglesias Rodríguez, M | 1 |
Ureña Tapia, MM | 1 |
Roca Fusalba, A | 1 |
Williams, A | 1 |
Saxena, S | 1 |
Pollok, RC | 1 |
Alberti, H | 1 |
Huang, B | 3 |
Fludas, C | 1 |
Farley, A | 1 |
Wruble, LD | 1 |
Humphries, TJ | 2 |
Falk, GW | 1 |
Schmitt, C | 1 |
Collins, DW | 1 |
Whipple, J | 1 |
D'Amico, D | 1 |
Joelsson, B | 1 |
Dupas, JL | 1 |
Houcke, P | 1 |
Samoyeau, R | 1 |
McGuigan, JE | 1 |
Henning, JM | 1 |
Lukasik, N | 1 |
Freston, JW | 1 |
Raisch, DW | 1 |
Klaurens, LM | 1 |
Hayden, C | 1 |
Malagon, I | 1 |
Pulliam, G | 1 |
Fass, R | 2 |
Farup, PG | 1 |
Juul-Hansen, PH | 1 |
Cohen, JS | 1 |
Meyer, JH | 1 |
Lembo, A | 1 |
Elashoff, JD | 1 |
Mayer, EA | 1 |
Melton, ST | 1 |
Cimmino, A | 1 |
Pencyla, JL | 1 |
Rodriguez-Stanley, S | 1 |
Ciociola, AA | 1 |
Filinto, J | 1 |
Zubaidi, S | 1 |
Fitzgerald, S | 1 |
Hegedus, R | 1 |
Murthy, A | 1 |
Jokubaitis, L | 1 |
Holtmann, G | 1 |
Metz, M | 1 |
Loeffler, V | 1 |
Blum, AL | 1 |
Frazzoni, M | 1 |
Grisendi, A | 1 |
Lanzani, A | 1 |
Melotti, G | 1 |
De Micheli, E | 1 |
Allen, ML | 1 |
McIntosh, D | 1 |
Cagliola, AJ | 1 |
Bradstreet, TE | 1 |
Hetzel, DJ | 1 |
Reed, WD | 1 |
Narielvala, FM | 1 |
Mackinnon, M | 1 |
McCarthy, JH | 1 |
Mitchell, B | 1 |
Beveridge, BR | 1 |
Laurence, BH | 1 |
Gibson, GG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors[NCT01265550] | Phase 3 | 366 participants (Actual) | Interventional | 2012-08-13 | Completed | ||
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program[NCT03719170] | 208,266 participants (Actual) | Interventional | 2019-09-16 | Completed | |||
Prospective Study Assessing Patient Satisfaction of Symptom Control With Proton Pump Inhibitor Dosing Regimen[NCT02623816] | Phase 4 | 64 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
A Multi-center, Double-blind, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Sodium Alginate Oral Suspension (50 mg/ml) in Comparison to Omeprazole (20 mg/Cap) to Treat Non-erosive Gastro-esophageal Reflux Disease (NERD)[NCT01338077] | Phase 3 | 195 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788] | Phase 2/Phase 3 | 144 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
A Phase III, Multi-centre, Double-blind, Double-dummy, Randomised, Study to Assess the Superiority of Zegerid® 20 mg vs. Losec® 20 mg in the Rapid Relief of Heartburn Associated With GERD as on Demand Therapy[NCT01493089] | Phase 3 | 239 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
Economic Impact of Guidelines for Gastroesophageal Reflux Disease[NCT00057174] | 484 participants (Anticipated) | Interventional | Completed | ||||
"Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of On-Demand Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week [NCT00236392] | Phase 3 | 422 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534] | Phase 3 | 407 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 2 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 3 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 125 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 130 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 3 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 51 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 86 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 3 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 16 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 8 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 13 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 4 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 7 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 1 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 221 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 32 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 3 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 1 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 152 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 8 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 0 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 2 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 2 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 4 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 56 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 10 |
(NCT01265550)
Timeframe: Screening
Intervention | Participants (Count of Participants) |
---|---|
All Enrolled | 9 |
"Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months.~Failure; <50% improvement in the baseline GERD-HRQL score at 12 months or:~For patients randomized to Surgical Treatment: a.<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit.~For patients randomized to Active Medical or Placebo Medical Treatment:~a.inability to tolerate both study medications or b.For patients treated with desipramine, i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit." (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 7 |
Surgical Treatment Group | 18 |
Placebo Medical Treatment Group | 3 |
Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 2 |
Surgical Treatment Group | 5 |
Placebo Medical Treatment Group | 0 |
Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 3 |
Surgical Treatment Group | 12 |
Placebo Medical Treatment Group | 2 |
Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 0 |
Surgical Treatment Group | 3 |
Placebo Medical Treatment Group | 0 |
Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 1 |
Surgical Treatment Group | 7 |
Placebo Medical Treatment Group | 1 |
Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 1 |
Surgical Treatment Group | 1 |
Placebo Medical Treatment Group | 0 |
Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 0 |
Surgical Treatment Group | 0 |
Placebo Medical Treatment Group | 0 |
Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 0 |
Surgical Treatment Group | 0 |
Placebo Medical Treatment Group | 0 |
Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 0 |
Surgical Treatment Group | 0 |
Placebo Medical Treatment Group | 0 |
Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 0 |
Surgical Treatment Group | 0 |
Placebo Medical Treatment Group | 0 |
Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 7 |
Surgical Treatment Group | 14 |
Placebo Medical Treatment Group | 3 |
Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 1 |
Surgical Treatment Group | 1 |
Placebo Medical Treatment Group | 1 |
Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 0 |
Surgical Treatment Group | 0 |
Placebo Medical Treatment Group | 0 |
Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 3 |
Surgical Treatment Group | 10 |
Placebo Medical Treatment Group | 3 |
Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Medical Treatment Group | 2 |
Surgical Treatment Group | 5 |
Placebo Medical Treatment Group | 0 |
(NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Surgical Treatment Group | 14 |
(NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Surgical Treatment Group | 15 |
(NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Surgical Treatment Group | 18 |
(NCT01265550)
Timeframe: 12 months
Intervention | Participants (Count of Participants) |
---|---|
Surgical Treatment Group | 14 |
"The 15-symptom GSAS questionnaire includes measures of: Gastrointestinal distress, Regurgitation/heartburn and Upper respiratory manifestations. The outcome measures were the number, frequency, and severity of GSAS symptoms reported at 6 weeks. Measures were based on aggregate GSAS scores. Symptom numbers range from 0 to 15. Frequency is based on the total number of reported days of symptomatic episodes in the past week divided by the number of potential symptoms (number reported divided by 15 for GSAS score. The range for frequency score:0 to 7 with higher scores indicative of greater frequency of symptoms. Severity is the average distress score reported by individuals (zero if no symptoms). Symptom distress is based on a 4 point Likert scale (0= not at all, 1=somewhat, 2=quite a bit and 3=very much). The higher the score the worse outcome.~." (NCT02623816)
Timeframe: 6 weeks
Intervention | score on a scale (Mean) | ||
---|---|---|---|
GSAS Symptoms Score | GSAS Frequency Score | GSAS Severity Score | |
Optimal Dosing | 5.2 | 1.0 | 0.6 |
Sub-optimal Dosing | 8.5 | 2.2 | 1.0 |
Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: up to 14 days following treatment
Intervention | Minutes (Median) |
---|---|
Zegerid Group | 37.5 |
Losec Group | 37.5 |
Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: up to 14 days
Intervention | Minutes (Median) |
---|---|
Zegerid Group | 37.5 |
Losec Group | 37.5 |
Time to sustained total relief, defined as zero severity (no heartburn) on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: 14 days
Intervention | Minutes (Median) |
---|---|
Zegerid Group | 105.0 |
Losec Group | 105.0 |
percentage of patients who have achieved sustained partial response, sustained response, or sustained total relief, by 45 minutes (NCT01493089)
Timeframe: up to 14 days
Intervention | percentage of patients (Number) |
---|---|
Zegerid Group | 65 |
Losec Group | 62.2 |
Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 60 minutes (NCT01493089)
Timeframe: 14 days
Intervention | Percentage of patients (Number) |
---|---|
Zegerid Group | 74.4 |
Losec Group | 78.4 |
Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 90 minutes (NCT01493089)
Timeframe: 14 days
Intervention | Percentage of patients (Number) |
---|---|
Zegerid Group | 88.0 |
Losec Group | 85.6 |
12 reviews available for omeprazole and Pyrosis
Article | Year |
---|---|
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
Topics: Adult; Alginates; Dexlansoprazole; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gastrointes | 2023 |
Review article: the management of heartburn during pregnancy and lactation.
Topics: Alginates; Antacids; Breast Feeding; Contraindications, Drug; Female; Gastroesophageal Reflux; Gastr | 2020 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; | 2017 |
Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; O | 2008 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; | 2011 |
Epigastric pain in dyspepsia and reflux disease.
Topics: Abdominal Pain; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia; Gastroesophageal Reflux; He | 2003 |
Sleep issues in gastroesophageal reflux disease: beyond simple heartburn control.
Topics: Antacids; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitor | 2003 |
[Significance of PPI-test in the diagnosis of GERD].
Topics: Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors | 2004 |
Clinical strategies -- interactive case discussions.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Female; Heartburn; Humans; Male; Middle Aged; Omeprazole | 2004 |
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D | 2004 |
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive Sys | 2006 |
A practical approach to heartburn.
Topics: Anti-Ulcer Agents; Circadian Rhythm; Drug Administration Schedule; Drug Therapy, Combination; Female | 1999 |
66 trials available for omeprazole and Pyrosis
Article | Year |
---|---|
Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial.
Topics: Abdominal Pain; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Esophagitis; Heartburn; Humans; O | 2023 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial).
Topics: Adult; Aged; Drug Administration Schedule; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; | 2019 |
The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study.
Topics: Adult; Aged; Aged, 80 and over; Alginates; Double-Blind Method; Drug Therapy, Combination; Female; G | 2019 |
Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.
Topics: Administration, Oral; Adult; Alginates; Double-Blind Method; Female; Gastroesophageal Reflux; Gastro | 2013 |
Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial.
Topics: Adult; Double-Blind Method; Female; Fluoxetine; Heartburn; Humans; Male; Middle Aged; Omeprazole; Pr | 2014 |
Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Drug Combinations; Female; Gastric Mucosa; Gastroesoph | 2015 |
Comparative clinical evaluation on herbal formulation Pepsil, Safoof-e-Katira and Omeprazole in gastro esophageal reflux disease.
Topics: Astragalus gummifer; Coriandrum; Deglutition Disorders; Female; Gastroesophageal Reflux; Heartburn; | 2015 |
Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 C | 2008 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastr | 2009 |
The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration.
Topics: Adult; Drug Administration Schedule; Esophageal pH Monitoring; Esophagitis; Esophagoscopy; Female; G | 2010 |
Gastroesophageal reflux disease management according to contemporary international guidelines: a translational study.
Topics: Adult; Esophagitis; Female; Gastroesophageal Reflux; Guidelines as Topic; Heartburn; Humans; Male; M | 2011 |
Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.
Topics: Adult; Aged; Alginates; Deglutition Disorders; Drug Therapy, Combination; Female; Gastroesophageal R | 2012 |
Combination of PPI with a prokinetic drug in gastroesophageal reflux disease.
Topics: Administration, Oral; Adult; Antiemetics; Domperidone; Double-Blind Method; Drug Synergism; Drug The | 2011 |
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2002 |
Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Health Status; Heartburn; He | 2003 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2003 |
Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Respon | 2003 |
Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Cross- | 2003 |
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials.
Topics: Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastroesophageal Reflux | 2003 |
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blin | 2004 |
On-demand PPI requirements in patients with endoscopy-negative GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Capsules; Drug Administrati | 2004 |
The effect of Helicobacter pylori eradication on gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2004 |
Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn.
Topics: Adult; Antacids; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule | 2005 |
Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Drug Administrat | 2005 |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug | 2005 |
Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis.
Topics: Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Capsules; Double-Blind Method; Esomeprazole; E | 2005 |
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Administration, Oral; Adult; Benzimidazoles; Cr | 2005 |
Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Topics: Analysis of Variance; Anti-Ulcer Agents; Drug Therapy, Combination; Famotidine; Female; Gastroesopha | 2005 |
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female | 2005 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Re | 2005 |
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Cross-Over Studies | 1995 |
Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis.
Topics: Adult; Antacids; Circadian Rhythm; Drug Therapy, Combination; Esophagitis, Peptic; Female; Gastroeso | 1993 |
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Meth | 1997 |
Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Antidiarrheals; Cross-Over Studies; Double-Blind Method; Endoscopy, Digesti | 1997 |
Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Cimetidine; Double-Blind Method; Esophagitis; Female; Ga | 1997 |
Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female; Ga | 1997 |
Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Female; Gastroesophageal Reflu | 1997 |
Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Female; G | 1997 |
The ambulatory pH study is normal, but the patient is not--the importance of the symptoms index.
Topics: Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Esophagus; Female; Gastroesophage | 1998 |
The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected].
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Alginates; Anti-Ulcer Agents; Biocompati | 1998 |
Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis.
Topics: Administration, Oral; Anti-Ulcer Agents; Chi-Square Distribution; Cimetidine; Double-Blind Method; E | 1998 |
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition | 1998 |
Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1999 |
Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1999 |
Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Female; Gastro | 1999 |
Heartburn treatment in primary care: randomised, double blind study for 8 weeks.
Topics: Anti-Ulcer Agents; Cisapride; Double-Blind Method; Female; Heartburn; Humans; Male; Middle Aged; Nor | 1999 |
On demand therapy of reflux oesophagitis--a prospective study of symptoms, patient satisfaction and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Gastric | 1999 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; A | 2000 |
Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Benzimidazoles; D | 2000 |
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Hear | 2000 |
Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2001 |
Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2001 |
Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2001 |
Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole.
Topics: Anti-Ulcer Agents; Cross-Over Studies; Drug Administration Schedule; Female; Gastric Acid; Gastric A | 2002 |
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis | 2002 |
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2002 |
Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Esophagus; Female; Gastroesophag | 1991 |
Healing and relapse of severe peptic esophagitis after treatment with omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Esop | 1988 |
54 other studies available for omeprazole and Pyrosis
Article | Year |
---|---|
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph | 2022 |
Successful Treatment of Refractory Lymphocytic Esophagitis With Vedolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Budesonide; Deglutition Disorders; Endoscopy, Digestive Sy | 2019 |
Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat.
Topics: Drug Administration Schedule; Dyspepsia; Evidence-Based Medicine; Gastric Acid; Gastric Mucosa; Gast | 2009 |
Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results.
Topics: Adult; Aged; Aged, 80 and over; Botulinum Toxins, Type A; Catheterization; Cohort Studies; Combined | 2010 |
If I take the blood thinner Plavix, should I avoid using Prilosec or other heartburn medications?
Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Health Knowledge, Atti | 2010 |
Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Drug Administration Schedul | 2011 |
Ask the doctor. I recently switched from Prilosec to its generic form omeprazole, and it doesn't relieve my heartburn as well as Prilosec. Aren't generics supposed to be the same as the brand-name drugs?
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drugs, Generic; Heartburn; Humans; Omeprazole; | 2012 |
[Adverse events associated with long-term use of proton pump inhibitors].
Topics: Anti-Ulcer Agents; Bacterial Infections; Congenital Abnormalities; Dyspepsia; Fractures, Bone; Gastr | 2012 |
[Typical and atypical symptoms of laryngopharyngeal reflux disease].
Topics: Adult; Anti-Ulcer Agents; Diagnosis, Differential; Esophagus; Female; Gastroesophageal Reflux; Heart | 2002 |
Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression?
Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2002 |
Over-the-counter omeprazole (prilosec OTC).
Topics: Enzyme Inhibitors; H(+)-K(+)-Exchanging ATPase; Heartburn; Humans; Nonprescription Drugs; Omeprazole | 2003 |
Omeprazole-induced intractable cough.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Cough; Female; Heartburn; Humans; Omeprazole | 2003 |
Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity.
Topics: Adult; Anti-Ulcer Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Female; Gastro | 2003 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoscopy, Gastrointestinal; Esophagitis; Female; He | 2003 |
[The proton pump especially steady in grip. Fast help for nightly reflux complaints].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Heartburn; Humans; Omepr | 2003 |
Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Anticonvulsants; Consumer Product Safety; Drug Labeling; Femal | 2004 |
[When sour does not make merry at all . Fast relief for patients with reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr | 2003 |
Second opinion. I have tried the new over-the-counter drug Prilosec for my heartburn, and it was very helpful. The package says I should take it for only two weeks and that if my heartburn comes back after that, I should see my doctor. If Prilosec helps,
Topics: Anti-Ulcer Agents; Heartburn; Humans; Omeprazole; Time Factors | 2004 |
One on one. I often have heartburn. Is it safe to use Prilosec OTC long term?
Topics: Heartburn; Humans; Omeprazole | 2004 |
Neuropathy associated with lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Heartburn; Humans; Lansop | 2005 |
Validation of the Reflux Disease Questionnaire for a German population.
Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Cultural Comparison; Dyspepsia; Female; Gastroesophageal Reflu | 2005 |
Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment.
Topics: Adult; Biopsy; Epithelial Cells; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Ma | 2005 |
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa | 2005 |
Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole.
Topics: Adult; Drug Administration Schedule; Female; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Io | 2005 |
Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aerophagy; Anti-Ulcer Agents; Benzimidazoles; Dose-R | 2005 |
A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Benzimidazoles; Gastric Acid; Gastric Acidity D | 2005 |
Psychological factors as a predictor of treatment response in patients with heartburn: a pooled analysis of clinical trials.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Anxiety; Child; Child, Preschool; Endoscopy, Gastrointes | 2006 |
Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy.
Topics: Adult; Aged; Case-Control Studies; Deglutition Disorders; Electric Impedance; Enzyme Inhibitors; Eso | 2006 |
[Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation; Cla | 2007 |
Responsiveness of measures of heartburn improvement in non-erosive reflux disease.
Topics: Adult; Aged; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Mid | 2007 |
Treatment of pyrosis does not insure adequate control of gastric acid reflux.
Topics: Barrett Esophagus; Chronic Disease; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Hydroge | 1995 |
Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy.
Topics: Case-Control Studies; Chronic Disease; Cough; Female; Fundoplication; Gastroesophageal Reflux; Heart | 1995 |
The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole.
Topics: Adult; Aged; Deglutition Disorders; Dose-Response Relationship, Drug; Esophagus; Female; Gastroesoph | 1993 |
[Retrosternal pain. Clinical conference about a subject with esophagitis].
Topics: Esophagitis, Peptic; Esophagoscopy; Female; Gastroesophageal Reflux; Heartburn; Humans; Manometry; M | 1993 |
Omeprazole maintenance therapy for GERD.
Topics: Adult; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Double-Blind Method; Gastroesophageal | 1997 |
Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study.
Topics: Anti-Ulcer Agents; Cough; Deglutition Disorders; Female; Follow-Up Studies; Gastroesophageal Reflux; | 1997 |
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Esophagitis, Peptic; Gastric Acidity Dete | 1998 |
The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cisapride; | 1999 |
Gastroesophageal reflux disease and a HAPPI quality of life.
Topics: Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors; Quality of Life | 1999 |
By the way, doctor. I take 10 mg of Prilosec about four times each week to control my heartburn. Does taking this drug on a continuing basis affect my body's ability to utilize nutrients in food?
Topics: Anti-Ulcer Agents; Digestion; Heartburn; Humans; Intestinal Absorption; Omeprazole | 1999 |
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Male; M | 1999 |
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Male; M | 1999 |
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Male; M | 1999 |
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Male; M | 1999 |
[Analysis of indications and diagnosis of the gastroscopies requested by primary care physicians].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Drug | 2000 |
Heartburn treatment in primary care. Prescribing omeprazole would conflict with desire to control prescribing costs.
Topics: Anti-Ulcer Agents; Costs and Cost Analysis; Drug Administration Schedule; Heartburn; Humans; Omepraz | 2000 |
Heartburn treatment in primary care. Step up approach to management is best.
Topics: Antacids; Anti-Ulcer Agents; Costs and Cost Analysis; Heartburn; Humans; Omeprazole | 2000 |
Heartburn treatment in primary care. Study's results seem to be promotional rather than evidence based.
Topics: Advertising; Anti-Ulcer Agents; Costs and Cost Analysis; Heartburn; Humans; Omeprazole | 2000 |
[Heartburn. Only a harmless symptom?].
Topics: Esophagitis, Peptic; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors | 2001 |
Treatment of gastroesophageal reflux disease: to step or not to step.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Hist | 2001 |
Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Formularies as Topic; Gastroesophageal Reflux; Heal | 2001 |
Clinical and ethical concerns about switching patient treatment to "therapeutically interchangeable" medications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Pathways; Esophagitis, Peptic; Ethics, Medical; He | 2001 |
Duodenal fat intensifies the perception of heartburn.
Topics: Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Dietary Fats; Dose-Response Relationship, Drug | 2001 |
What is the best pharmacologic approach to managing moderate to severe heartburn?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Female; Heartburn; Histamine H2 | 2001 |
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Fundop | 2002 |